Keywords: pfzizer, geodon, fares, well, vs, placebo, zyprexa
Pfzizer's Geodon fares well vs placebo and Zyprexa
Article | 15 August 2005
Pfizer, the world's largest drugmaker, says that its antipsychotic Geodon (ziprasidone) produces a significant improvements in patients with bipolar mania ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
